Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Odile Launay

Showing results (181-190 of 305) with videos related to

Pageof 31
Sort By:
Vaccine|July 25, 2018
A report on the status of vaccination in EuropeShazia Sheikh, Eliana Biundo, Soizic Courcier, et al.
BMC Infectious Diseases|May 16, 2019
Influenza epidemiology and influenza vaccine effectiveness during the 2015-2016 season: results from the Global Influenza Hospital Surveillance NetworkJoan Puig-Barberà, Ainara Mira-Iglesias, Elena Burtseva, et al.
AIDS (London, England)|August 11, 2018
Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patientsNathalie Colin de Verdiere, Christine Durier, Assia Samri, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 18, 2002
Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1Odile Launay, Laurence Gérard, Laurence Morand-Joubert, et al.
Human Vaccines & Immunotherapeutics|March 28, 2023
Immunogenicity and safety of the non-typable <i>Haemophilus influenzae</i>-<i>Moraxella catarrhalis</i> (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trialIlaria Galgani, Airi Põder, Rain Jõgi, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|September 28, 2017
The value of molecular techniques to diagnose Ureaplasma urealyticum and Nocardia farcinica pleuropneumonia in a patient with diffuse large B-cell lymphomaEtienne Canouï, Kim Blanc, Julien Loubinoux, et al.
Vaccine|July 16, 2013
Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16)Odile Launay, Mathieu Surenaud, Corinne Desaint, et al.
NPJ Vaccines|April 15, 2021
Accelerated phase Ia/b evaluation of the malaria vaccine candidate PfAMA1 DiCo demonstrates broadening of humoral immune responsesEdmond J Remarque, Bart W Faber, Roberto Rodriguez Garcia, et al.
Rheumatology (Oxford, England)|January 25, 2011
Patients with systemic inflammatory and autoimmune diseases are at risk of vaccine-preventable illnessesCecile Marchand-Janssen, Pierre Loulergue, Luc Mouthon, et al.
Vaccine|March 10, 2026
Ancestral Wuhan SARS-CoV-2 anti-spike CD4<sup>+</sup> T cells predict protection from symptomatic omicron breakthrough infectionChristine Durier, Nadine Benhamouda, Anissa Besbes, et al.
Pageof 31

Showing results (181-190 of 305) with videos related to

Sort By:
Pageof 31
Vaccine|July 25, 2018
A report on the status of vaccination in EuropeShazia Sheikh, Eliana Biundo, Soizic Courcier, et al.
BMC Infectious Diseases|May 16, 2019
Influenza epidemiology and influenza vaccine effectiveness during the 2015-2016 season: results from the Global Influenza Hospital Surveillance NetworkJoan Puig-Barberà, Ainara Mira-Iglesias, Elena Burtseva, et al.
AIDS (London, England)|August 11, 2018
Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patientsNathalie Colin de Verdiere, Christine Durier, Assia Samri, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 18, 2002
Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1Odile Launay, Laurence Gérard, Laurence Morand-Joubert, et al.
Human Vaccines & Immunotherapeutics|March 28, 2023
Immunogenicity and safety of the non-typable <i>Haemophilus influenzae</i>-<i>Moraxella catarrhalis</i> (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trialIlaria Galgani, Airi Põder, Rain Jõgi, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|September 28, 2017
The value of molecular techniques to diagnose Ureaplasma urealyticum and Nocardia farcinica pleuropneumonia in a patient with diffuse large B-cell lymphomaEtienne Canouï, Kim Blanc, Julien Loubinoux, et al.
Vaccine|July 16, 2013
Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16)Odile Launay, Mathieu Surenaud, Corinne Desaint, et al.
NPJ Vaccines|April 15, 2021
Accelerated phase Ia/b evaluation of the malaria vaccine candidate PfAMA1 DiCo demonstrates broadening of humoral immune responsesEdmond J Remarque, Bart W Faber, Roberto Rodriguez Garcia, et al.
Rheumatology (Oxford, England)|January 25, 2011
Patients with systemic inflammatory and autoimmune diseases are at risk of vaccine-preventable illnessesCecile Marchand-Janssen, Pierre Loulergue, Luc Mouthon, et al.
Vaccine|March 10, 2026
Ancestral Wuhan SARS-CoV-2 anti-spike CD4<sup>+</sup> T cells predict protection from symptomatic omicron breakthrough infectionChristine Durier, Nadine Benhamouda, Anissa Besbes, et al.
Pageof 31